Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026)
Xilio Therapeutics' (XLO) quarterly Asset Utilization Ratio came in at 0.34 in Q1 2026, up 216.82% year-on-year from 0.11 in Q1 2025, and up 10.76% quarter-over-quarter from 0.3 in Q4 2025.
Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Xilio Therapeutics has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.34 for Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.34, up 216.82% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.34 (up 216.82% YoY), and the FY2025 annual result was 0.39, up 303.37% from the prior year.
- Asset Utilization Ratio came in at 0.34 for Q1 2026 at Xilio Therapeutics, up from 0.3 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.34 in Q1 2026 to a low of 0.11 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xilio Therapeutics | 144.35 Mn | -5.95 Mn | - | 0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.24 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.11 |